Alexza Pharmaceuticals (ALXA) 10-Q 7 Aug 14 2014 Q2 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Jun. 30, 2014	Jul. 31, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Jun-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q2	'
Trading Symbol	'ALXA	'
Entity Registrant Name	'Alexza Pharmaceuticals Inc.	'
Entity Central Index Key	'0001344413	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Common Stock, Shares Outstanding	'	17,370,930

Condensed_Consolidated_Balance

Condensed Consolidated Balance Sheets (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets:	'	'
Cash and cash equivalents	$10,517	$17,306	[1]
Marketable securities	33,084	8,578	[1]
Receivables	1,018	129	[1]
Inventory	3,974	3,447	[1]
Prepaid expenses and other current assets	2,913	1,453	[1]
Total current assets	51,506	30,913	[1]
Property and equipment, net	15,782	14,991	[1]
Restricted cash	5,562	0	[1]
Other assets	3,482	1,168	[1]
Total assets	76,332	47,072	[1]
Current liabilities:	'	'
Accounts payable	2,655	3,789	[1]
Accrued clinical trial expenses	342	178	[1]
Other accrued expenses	3,742	4,736	[1]
Current portion of contingent consideration liability	1,100	2,500	[1]
Current portion of financing obligations	398	780	[1]
Current portion of deferred revenue	1,457	2,915	[1]
Total current liabilities	9,694	14,898	[1]
Deferred rent	5,576	6,405	[1]
Noncurrent portion of contingent consideration liability	31,400	36,700	[1]
Noncurrent portion of deferred revenues	2,550	2,185	[1]
Noncurrent portion of financing obligations	62,995	10,744	[1]
Other noncurrent liabilities	476	115	[1]
Stockholders' deficit:	'	'
Preferred stock	0	0	[1]
Common stock	2	2	[1]
Additional paid-in-capital	354,562	350,250	[1]
Accumulated other comprehensive income	2	1	[1]
Deficit accumulated during development stage	-390,925	-374,228	[1]
Total stockholders' deficit	-36,359	-23,975	[1]
Total liabilities and stockholders' equity	$76,332	$47,072	[1]
[1]	The condensed consolidated balance sheet at December 31, 2013 has been derived from audited consolidated financial statements at that date.

Condensed_Consolidated_Stateme

Condensed Consolidated Statements of Loss and Comprehensive Loss (USD $)	3 Months Ended		6 Months Ended
Share data in Thousands, except Per Share data, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Income Statement [Abstract]	'	'	'	'
Collaboration revenue	$368,000	$43,529,000	$2,097,000	$44,258,000
Product sales	1,116,000	106,000	1,553,000	106,000
Total revenue	1,484,000	43,635,000	3,650,000	44,364,000
Operating expenses:	'	'	'	'
Cost of goods sold	4,903,000	2,961,000	8,694,000	2,961,000
Research and development	4,032,000	4,799,000	7,162,000	11,018,000
General and administrative	3,898,000	4,806,000	7,946,000	8,919,000
Total operating expenses	12,833,000	12,566,000	23,802,000	22,898,000
Loss from operations	-11,349,000	31,069,000	-20,152,000	21,466,000
(Loss)/gain on change in fair value of contingent consideration liability	7,599,000	-31,500,000	6,449,000	-42,400,000
Interest and other income/ (expense), net	2,000	4,000	8,000	17,000
Interest expense	-2,214,000	-372,000	-3,002,000	-594,000
Net loss	-5,962,000	-799,000	-16,697,000	-21,511,000
Basic and diluted net loss per share	($0.34)	($0.05)	($0.96)	($1.34)
Shares used to compute basic and diluted net loss per share	17,331	16,375	17,307	16,076
Other Comprehensive Loss	'	'	'	'
Change in unrealized gain/(loss) on marketable securities	2,000	5,000	1,000	5,000
Comprehensive loss	($5,960,000)	($794,000)	($16,696,000)	($21,506,000)

Condensed_Consolidated_Stateme1

Condensed Consolidated Statements of Cash Flows (USD $)	6 Months Ended
	Jun. 30, 2014		Jun. 30, 2013
Cash flows from operating activities:	'		'
Net loss	($16,697,000)		($21,511,000)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:	'		'
Share-based compensation	1,361,000		1,518,000
Change in fair value of contingent consideration liability	-6,449,000		42,400,000
Amortization of debt discount, deferred interest and right-to-borrow asset	1,027,000		153,000
Amortization of premium (discount) on available-for-sale securities	50,000		0
Depreciation and amortization	1,670,000		1,692,000
Gain on disposal of property	0		-15,000
Changes in operating assets and liabilities:	'		'
Receivables	-889,000		-106,000
Inventory	-527,000		-1,276,000
Prepaid expenses and other current assets	-626,000		-26,000
Other assets	0		-2,593,000
Accounts payable	-1,134,000		1,239,000
Accrued clinical and other accrued liabilities	-830,000		843,000
Deferred revenues	-1,093,000		-1,457,000
Other liabilities	-468,000		-847,000
Net cash used in operating activities	-24,605,000		20,014,000
Cash flows from investing activities:	'		'
Purchases of available-for-sale securities	-33,130,000		-9,143,000
Maturities of available-for-sale securities	8,575,000		0
Purchases of property and equipment	-2,461,000		-906,000
Proceeds from sale of property and equipment	0		16,000
Net cash provided by (used in) investing activities	-27,016,000		-10,033,000
Cash flows from financing activities:	'		'
Proceeds from issuance of common stock and warrants and exercise of stock options and stock purchase rights	198,000		6,414,000
Change in restricted cash	-5,562,000		5,051,000
Payment on contingent consideration liability	-251,000		-10,000,000
Proceeds from financing obligations, net of issuance costs	50,830,000		0
Payments of financing obligations	-383,000		-3,308,000
Net cash provided by financing activities	44,832,000		-1,843,000
Net increase (decrease) in cash and cash equivalents	-6,789,000		8,138,000
Cash and cash equivalents at beginning of period	17,306,000	[1]	17,715,000
Cash and cash equivalents at end of period	10,517,000		25,853,000
Non cash investing and financing activities:	'		'
Value of warrants issued with royalty securitization financing	1,721,000		0
Value of the beneficial conversion feature related to borrowings against the Teva Note	1,032,000		0
Value of right-to-borrow asset reclassified as debt discount	$570,000		$0
[1]	The condensed consolidated balance sheet at December 31, 2013 has been derived from audited consolidated financial statements at that date.

The_Company_and_Basis_of_Prese

The Company and Basis of Presentation	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
The Company and Basis of Presentation	'
	1. The Company and Basis of Presentation
	Business
	We were incorporated in the state of Delaware on December 19, 2000 as FaxMed, Inc., changed our name to Alexza Corporation in June 2001 and in December 2001 became Alexza Molecular Delivery Corporation. In July 2005, we changed our name to Alexza Pharmaceuticals, Inc.
	We are a pharmaceutical company focused on the research, development, and commercialization of novel proprietary products for the acute treatment of central nervous system conditions. We operate in one business segment. Our facilities and employees are currently located in the United States.
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not contain all of the information and footnotes required for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim condensed consolidated financial information. The results for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other interim period or any other future year.
	The accompanying unaudited condensed consolidated financial statements and notes to condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2013 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 25, 2014.
	Basis of Consolidation
	The unaudited condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	2. Summary of Significant Accounting Policies
	Revenue Recognition
	We recognize revenue when (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Prior to the second quarter of 2013, our revenue consisted primarily of amounts earned from collaboration agreements and under research grants with the National Institutes of Health. Beginning in the second quarter of 2013, we also have revenue from product sales.
	For collaboration agreements, revenues for non-refundable upfront license fee payments, where we continue to have performance obligations, are recognized as performance occurs and obligations are completed. Revenues for non-refundable upfront license fee payments where we do not have significant future performance obligations are recognized when the agreement is signed and the payments are due.
	For multiple element arrangements, such as collaboration agreements in which a collaborator may purchase several deliverables, we account for each deliverable as a separate unit of accounting if both of the following criteria are met: (i) the delivered item or items have value to the customer on a standalone basis; and (ii) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. We evaluate how the consideration should be allocated among the units of accounting and allocate revenue to each non-contingent element based upon the relative selling price of each element. We determine the relative selling price for each deliverable using (i) vendor-specific objective evidence, or VSOE, of selling price if it exists; (ii) third-party evidence, or TPE, of selling price if it exists; or (iii) our best estimated selling price for that deliverable if neither VSOE nor TPE of selling price exists for that deliverable. We then recognize the revenue allocated to each element when the four basic revenue criteria described above are met for each element.
	For milestone payments received in connection with our collaboration agreements, we have elected to adopt the milestone method of accounting under Financial Accounting Standards Board Accounting Standards Codification 605-28, Milestone Method. Under the milestone method, revenues for payments which meet the definition of a milestone will be recognized as the respective milestones are achieved.
	We recognize product revenue as follows:
		•		Persuasive Evidence of an Arrangement. We currently sell product through license and supply agreements with our collaborators, Grupo Ferrer Internacional, S.A., or Ferrer, and Teva Pharmaceuticals USA, Inc., or Teva. Persuasive evidence of an arrangement is generally determined by the receipt of an approved purchase order from the collaborator in connection with the terms of the related license and supply agreements.
		•		Delivery. Typically, ownership of the product passes to the collaborator upon shipment. Our current license and supply agreements also provide our collaborators with an acceptance period during which they may reject any product which does not conform to agreed-upon specifications. Because ADASUVE is a new product, a new technology and our first product to be commercialized, and because we do not have a history of producing product to collaborator specifications, we will not consider delivery to have occurred until after the collaborator acceptance period has ended or the collaborator has positively accepted the product. Once we have demonstrated over the course of time an ability to reliably produce the product to collaborator specifications, we will consider delivery to have occurred upon shipment in the absence of any other relevant shipment or acceptance terms.
		•		Sales Price Fixed or Determinable. Sales prices for product shipments are determined by license and supply agreements and documented in purchase orders. After the collaborator acceptance period has ended or the collaborator has positively accepted the product, our collaborators do not have any product return or replacement rights, including for expired products.
		•		Collectability. Payment for the product is contractually obligated under the license and supply agreements. We will monitor payment histories for our collaborators and specific issues as they arise to determine whether collection is probable for a specific transaction and defer revenue as necessary.
	Royalty revenue from our collaboration agreements will be recognized as we receive information from our collaborators regarding product sales and collectability is reasonably assured.
	Significant management judgment is used in the determination of revenue to be recognized and the period in which it is recognized.
	Inventory
	Inventory is stated at standard cost, which approximates actual cost, determined on a first-in first-out basis, not in excess of market value. Inventory includes the direct costs incurred to manufacture products combined with allocated manufacturing overhead, which consists of indirect costs, including labor and facility overhead. We are in the early stages of commercialization and have incurred significantly higher than normal indirect costs in the production of our inventory due to start-up manufacturing costs and low production volumes. The carrying cost of inventory is reduced so as to not be in excess of the market value of the inventory as determined by the contractual transfer prices to Ferrer and Teva. The excess over the market value is expensed to cost of goods sold. All costs associated with the ADASUVE manufacturing process incurred prior to regulatory approval and the beginning of commercial manufacturing were expensed as a component of research and development expense. If information becomes available that suggests that all or certain of the inventory may not be realizable, we may be required to expense a portion, or all, of the capitalized inventory into cost of goods sold. Inventory, which is stated at the lower of cost or estimated market value, consists of the following at June 30, 2014 and December 31, 2013 (in thousands):
			June 30,		December 31,
			2014		2013
	Raw materials		$	3,857	$	3,044
	Work in process			117		—
	Finished goods			—		403
	Total inventory		$	3,974	$	3,447
	New Accounting Pronouncement
	In May 2014 the Financial Accounting Standards Board, or (FASB, issued the Accounting Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606), that will supersede nearly all existing revenue recognition guidance under US GAAP. The core principle of the guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard will be effective for public entities for annual and interim periods beginning after December 15, 2016.
	Entities can choose to apply the standard using either the full retrospective approach or a modified retrospective approach. Entities electing the full retrospective adoption will apply the standard to each period presented in the financial statements. This means that entities will have to apply the new guidance as if it had been in effect since the inception of all its contracts with customers presented in the financial statements. Entities that elect the modified retrospective approach will apply the guidance retrospectively only to the most current period presented in the financial statements. This means that entities will have to recognize the cumulative effect of initially applying the new standard as an adjustment to the opening balance of retained earnings at the date of initial application. The new revenue standard will be applied to contracts that are in progress at the date of initial application.
	We plan to adopt the new standard on January 1, 2017. We have not yet evaluated which adoption method we plan to use or the potential effect the new standard will have on our consolidated financial statements.

Fair_Value_Accounting

Fair Value Accounting	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Fair Value Accounting	'
	3. Fair Value Accounting
	Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Three levels of inputs, of which the first two are considered observable and the last unobservable, may be used to measure fair value. The three levels are:
		•		Level 1 — Quoted prices in active markets for identical assets or liabilities.
		•		Level 2 — Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
		•		Level 3 — Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) by major security type and contingent consideration liability measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013 (in thousands):
	June 30, 2014		Level 1			Level 2			Level 3			Total
	Assets
	Money market funds		$	10,917		$	—		$	—		$	10,917
	Corporate debt securities			—			38,023			—			38,023
	Total assets		$	10,917		$	38,023		$	—		$	48,940
	Liabilities
	Contingent consideration liability		$	—		$	—		$	32,500		$	32,500
	Total liabilities		$	—		$	—		$	32,500		$	32,500
	December 31, 2013		Level 1			Level 2			Level 3			Total
	Assets
	Money market funds		$	11,345		$	—		$	—		$	11,345
	Corporate debt securities			—			12,003			—			12,003
	Total assets		$	11,345		$	12,003		$	—		$	23,348
	Liabilities
	Contingent consideration liability		$	—		$	—		$	39,200		$	39,200
	Total liabilities		$	—		$	—		$	39,200		$	39,200
	Cash equivalents and marketable securities
	The amortized cost, fair value and unrealized gain/(loss) for our financial assets by major security type as of June 30, 2014 and December 31, 2013 are as follows (in thousands):
	June 30, 2014		Amortized			Fair Value			Unrealized
			Cost						Gain/(Loss)
	Money market funds		$	10,917		$	10,917		$	—
	Corporate debt securities			38,021			38,023			2
	Total			48,938			48,940			2
	Less amounts classified as restricted cash			(5,562	)		(5,562	)
	Less amounts classified as cash equivalents			(10,294	)		(10,294	)		—
	Total marketable securities		$	33,082		$	33,084		$	2
	December 31, 2013		Amortized			Fair Value			Unrealized
			Cost						Gain/(Loss)
	Money market funds		$	11,345		$	11,345		$	—
	Corporate debt securities			12,002			12,003			1
	Total			23,347			23,348			1
	Less amounts classified as cash equivalents			(14,770	)		(14,770	)		—
	Total marketable securities		$	8,577		$	8,578		$	1
	We had no sales of marketable securities during the three or six months ended June 30, 2014 or 2013.
	Contingent Consideration Liability
	In connection with the exercise of our option to purchase all of the outstanding equity of Symphony Allegro, Inc., or Allegro, in 2009, we are obligated to make contingent cash payments to the former Allegro stockholders related to certain payments received by us from future collaboration agreements pertaining to ADASUVE/AZ-104 (Staccato loxapine) or AZ-002 (Staccato alprazolam). In order to estimate the fair value of the liability associated with the contingent cash payments, we prepared several cash flow scenarios for ADASUVE, AZ-104 and AZ-002, which are subject to the contingent payment obligation. Each potential cash flow scenario consisted of assumptions of the range of estimated milestone and license payments potentially receivable from such collaborations and assumed royalties received from future product sales. Based on these estimates, we computed the estimated payments to be made to the former Allegro stockholders. Payments were assumed to terminate in accordance with current agreement terms or, if no agreements exist, upon the expiration of the related patents.
	The projected cash flow assumptions for ADASUVE in the United States are based on the License and Supply Agreement, or the Teva Agreement, between us and Teva (see Note 9) and on internally and externally developed product sales forecasts. The timing and extent of the projected cash flows for ADASUVE for Europe, Latin America and the Commonwealth of Independent States countries, or the Ferrer Territories, are based on the Collaboration, License and Supply Agreement, or Ferrer Agreement, between us and Ferrer (see Note 9). The timing and extent of the projected cash flows for the remaining territories for ADASUVE and worldwide territories for AZ-002 and AZ-104 were based on internal estimates for potential milestones and multiple product royalty scenarios and are also consistent in structure to the most recently negotiated collaboration agreements.
	We then assigned a probability to each of the cash flow scenarios based on several factors, including: the product candidate’s stage of development, preclinical and clinical results, technological risk related to the successful development of the different drug candidates, estimated market size, market risk and potential collaboration interest to determine a risk adjusted weighted average cash flow based on all of these scenarios. These probability and risk adjusted weighted average cash flows were then discounted utilizing our estimated weighted average cost of capital, or WACC, of 16.5%. Our WACC considered our cash position, competition, risk of substitute products, and risk associated with the financing of the development projects.
	The fair value measurement of the contingent consideration liability is based on significant inputs not observed in the market and thus represents a Level 3 measurement. Level 3 measurements are valued based on unobservable inputs that are supported by little or no market activity and reflect our assumptions in measuring fair value.
	We record any changes in the fair value of the contingent consideration liability in earnings in the period of the change. Certain events including, but not limited to, the timing and terms of any collaboration agreement, clinical trial results, approval or non-approval of any future regulatory submissions and the commercial success of ADASUVE, AZ-104 or AZ-002 could have a material impact on the fair value of the contingent consideration liability, and as a result, our results of operations and financial position for the impacted period.
	During the three and six months ended June 30, 2014, we modified the assumptions associated with the amount and timing of milestones and royalties projected for ADASUVE and AZ-002, the probability that AZ-002 would be licensed or sold by us, and the effects of the passage of three and six months on the present value computation. These items resulted in a decrease to the contingent consideration liability and a corresponding non-operating gain of $7,599,000 and $6,449,000 or $0.44 and $0.37 per share, for the three and six months ended June 30, 2014, respectively.
	During the three and six months ended June 30, 2013, we modified the assumptions regarding the timing and amount of certain cash flows primarily to reflect the increased probability that we would license the U.S. commercialization rights to ADASUVE to a third party in the first quarter and the impact of the actual licensing and the terms of the Teva Agreement in the second quarter. These changes in assumptions, the change in the WACC in the second quarter of 2013 from 18.0% to 16.5%, the projected U.S. ADASUVE launch date in the first quarter of 2014 and the effects of the passage of three and six months on the present value computation resulted in an increase to the net loss of $31,500,000 and $42,400,000, or $1.92 and $2.64 per share, for the three and six months ended June 30, 2013, respectively.
	The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability for the three and six months ended June 30, 2014 and 2013 (in thousands):
			Three Months Ended						Six Months Ended
			June 30,						June 30,
			2014			2013			2014			2013
	Beginning balance		$	40,100		$	9,600		$	39,200		$	9,600
	Payments made			(1	)		—			(251	)		—
	Adjustments to fair value measurement			(7,599	)		10,900			(6,449	)		10,900
	Ending balance		$	32,500		$	20,500		$	32,500		$	20,500
	Financing Obligations
	We estimated the fair value of our financing obligations (see Note 7) using the net present value of the payments discounted at an interest rate that is consistent with our estimated current borrowing rate for similar long-term debt. We believe the estimates used to measure the fair value of the financing obligations constitute Level 3 inputs.
	At June 30, 2014 and December 31, 2013, the estimated fair value of our financing obligations was $56,135,000 and $9,342,000, respectively and had book values of $63,393,000 and $11,524,000, respectively. Our payment commitments associated with these debt instruments may vary with changes in interest rates and are comprised of interest payments and principal payments. The fair value of our debt will fluctuate with movements of interest rates, increasing in periods of declining rates of interest, and declining in periods of increasing rates of interest.

ShareBased_Compensation_Plans

Share-Based Compensation Plans	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-Based Compensation Plans	'
	4. Share-Based Compensation Plans
	2005 Equity Incentive Plan
	In December 2005, our Board of Directors adopted the 2005 Equity Incentive Plan, or the 2005 Plan. The 2005 Plan became effective upon the closing of our initial public offering on March 8, 2006. The 2005 Plan is an amendment and restatement of our previous stock option plans.
	The 2005 Plan provides for annual reserve increases on the first day of each fiscal year commencing on January 1, 2007 and ending on January 1, 2015. The annual reserve increases will be equal to the lesser of (i) 2% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year, or (ii) 100,000 shares of common stock. Our Board of Directors has the authority to designate a smaller number of shares by which the authorized number of shares of common stock will be increased prior to the last day of any calendar year.
	2005 Non-Employee Directors’ Stock Option Plan
	In December 2005, our Board of Directors adopted the 2005 Non-Employee Directors’ Stock Option Plan, or the Directors’ Plan. The Directors’ Plan provides for the automatic grant of nonstatutory stock options to purchase shares of common stock to our non-employee directors, which vest over four years and have a term of 10 years. The Directors’ Plan provides for an annual reserve increase to be added on the first day of each fiscal year, commencing on January 1, 2007 and ending on January 1, 2015. The annual reserve increases will be equal to the number of shares subject to options granted during the preceding fiscal year less the number of shares that revert back to the share reserve during the preceding fiscal year. Our Board of Directors has the authority to designate a smaller number of shares by which the authorized number of shares of common stock will be increased prior to the last day of any calendar year.
	The following table sets forth the summary of option activity under our share-based compensation plans for the six months ended June 30, 2014:
		Outstanding Options
		Number of			Weighted Average
		Shares			Exercise Price
	Outstanding at January 1, 2014		2,121,504		$	7.53
	Options granted		999,200			4.81
	Options exercised		(18,768	)		3.47
	Options canceled		(244,023	)		5.76
	Outstanding at June 30, 2014		2,857,913			6.76
	The intrinsic value of options exercised during the three and six months ended June 30, 2014 was $16,000 and $21,000, respectively. There was no total intrinsic value of options exercised during the three and six months ended June 30, 2013.
	The following table sets forth the summary of restricted stock unit activity under our share-based compensation plans for the six months ended June 30, 2014:
		Number			Weighted
		Of			Average
		Shares			Grant-Date
					Fair Value
	Outstanding at January 1, 2014		521,050		$	4.68
	Granted		—			—
	Released		(31,825	)		4.68
	Forfeited		(95,750	)		4.68
	Outstanding at June 30, 2014		393,475		$	4.68
	In May 2013, our stockholders approved an amendment to the 2005 Plan and the Directors’ Plan to increase the shares authorized for issuance by 2,200,000 shares and 200,000 shares, respectively. On January 1, 2014 and 2013 an additional 100,000 shares were authorized for issuance under the evergreen provisions of the 2005 Plan. On January 1, 2014 and 2013, an additional 58,751 shares and 19,812 shares, respectively, were authorized for issuance under the evergreen provisions of the Directors’ Plan.
	As of June 30, 2014, 465,969 and 150, 000 shares remained available for issuance under the 2005 Plan and the Directors’ Plan, respectively.
	2005 Employee Stock Purchase Plan
	The Employee Stock Purchase Plan, or ESPP, allows eligible employee participants to purchase shares of our common stock at a discount through payroll deductions. The ESPP consists of a six-month fixed offering period. Purchases are generally made on the last trading day of each October and April. Employees purchase shares at each purchase date at 85% of the market value of our common stock on the beginning or the end of the purchase period, whichever price is lower.
	The ESPP provides for annual reserve increases on the first day of each fiscal year commencing on January 1, 2007 and ending on January 1, 2015. The annual reserve increases are equal to the least of (i) 1% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year, (ii) 75,000 shares of common stock, or (iii) a lesser amount determined by our Board of Directors.
	We issued 37,096 shares at a weighted average price of $3.63 under the ESPP during the three and six months ended June 30, 2014 and 18,843 shares at a weighted average price of $3.65 under the ESPP during the three and six months ended June 30, 2013. At June 30, 2014, 112,536 shares were available for issuance under the ESPP.

ShareBased_Compensation

Share-Based Compensation	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Share-Based Compensation	'
	5. Share-Based Compensation
	Employee Share-Based Awards
	Compensation cost for employee share-based awards is based on the grant-date fair value and is recognized over the vesting period of the applicable award on a straight-line basis. We issue employee share-based awards in the form of stock options and restricted stock units under our equity incentive plans, and stock purchase rights under the ESPP.
	Valuation of Stock Options, Stock Purchase Rights and Restricted Stock Units
	During the three and six months ended June 30, 2014 and 2013, the per share weighted average fair value of employee stock options granted were as follows:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Stock options	$	2.95		$	3.47		$	3.2		$	3.46
	Restricted stock units		—			4.68			—			4.67
	Stock purchase rights		1.48			1.41			1.48			1.53
	The estimated grant date fair values of the stock options and stock purchase rights were calculated using the Black-Scholes valuation model, and the following weighted average assumptions:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Stock Option Plans
	Expected term		5.0 years			5.0 years			5.0 years			5.0 years
	Expected volatility		82	%		100	%		84	%		100	%
	Risk-free interest rate		1.65	%		0.84	%		1.61	%		0.77	%
	Dividend yield		0	%		0	%		0	%		0	%
	Employee Stock Purchase Plan
	Expected term		0.5 years			0.5 years			0.5 years			0.5 years
	Expected volatility		61	%		63	%		61	%		70	%
	Risk-free interest rate		0.67	%		0.12	%		0.67	%		0.13	%
	Dividend yield		0	%		0	%		0	%		0	%
	The estimated fair value of restricted stock unit awards is calculated based on the market price of our common stock on the date of grant, reduced by the present value of dividends expected to be paid on our common stock prior to vesting of the restricted stock unit. Our estimate assumes no dividends will be paid prior to the vesting of the restricted stock unit.
	As of June 30, 2014, there was $5,321,000, $1,328,000, and $44,000 of total unrecognized compensation expense related to unvested stock option awards, unvested restricted stock units and stock purchase rights, respectively, which are expected to be recognized over a weighted average period of 2.6 years, 2.4 years, and 0.3 years, respectively.
	Share-based compensation capitalized at June 30, 2014 was not material.

Net_Loss_per_Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Net Loss per Share	'
	6. Net Loss per Share
	Basic and diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares outstanding for the period. The following items were excluded from the net loss per share calculation for the three and six months ended June 30, 2014 and 2013 because the inclusion of such items would have had an anti-dilutive effect:
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Stock options		2,584,615		1,526,083		2,430,244		1,363,470
	Restricted stock units		435,388		263,475		463,942		175,650
	Warrants to purchase common stock		6,807,727		6,462,066		6,692,507		6,462,066
	Convertible debt		4,951,459		—		4,416,222		—

Financing_Obligations

Financing Obligations	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Financing Obligations	'
	7. Financing Obligations
	Autoliv ASP, Inc.
	In June 2010, in return for transfer to us of all right, title and interest in a production line for the commercial manufacture of chemical heat packages completed or to be completed by Autoliv ASP, Inc., or Autoliv, on behalf of us, we paid Autoliv $4,000,000 in cash and issued Autoliv a $4,000,000 unsecured promissory note. In February 2011, we entered into an agreement to amend the terms of the unsecured promissory note. Under the terms of that amendment, the original $4,000,000 note was cancelled and a new unsecured promissory note was issued with a reduced principal amount of $2,800,000, or the New Note. The New Note bears interest beginning on January 1, 2011 at 8% per annum and is being paid in 48 consecutive and equal monthly installments of approximately $68,000.
	Teva Pharmaceuticals USA, Inc.
	In May 2013, concurrent with the Teva Agreement (see Note 9), we entered into a Convertible Promissory Note and Agreement to Lend, dated as of May 7, 2013, between us and Teva, or the Teva Note. Under the terms of the Teva Note, we may, upon written notice to Teva, draw upon the Teva Note to fund agreed operating budgets related to ADASUVE. The aggregate drawdowns may total up to $25,000,000 and will be due and payable, together with all interest, on the fifth anniversary of the signing of the Teva Note. We may prepay, from time to time, up to one-half of the total amounts advanced plus the related interest outstanding at any time prior to the maturity date. At any time prior to five days before the maturity date, Teva will have the right to convert the then outstanding amounts into shares of our common stock at a conversion price of $4.4833 per share. The Teva Note bears simple interest of 4% per year. We have two years from the effective date of the Teva Note to receive advances. In 2013, we drew down a total of $15,000,000 against the Teva Note.
	In the third quarter of 2013, we drew down $10,000,000 against the Teva Note and, in the fourth quarter of 2013, we drew down an additional $5,000,000 against the Teva Note. At the time of the drawdowns, the contractual conversion price was less than the value of our common stock. As a result, we calculated the value of the beneficial conversion feature of the convertible note and recorded an increase to additional paid-in-capital and a discount on the Teva Note of $3,112,000 which will be amortized to interest expense over the life of the borrowing. Additionally, we reclassified the relative portion of the unamortized right-to-borrow (see Note 9) against the Teva Note in the amount of $1,293,000, which will also be amortized to interest expense over the life of the borrowing. The effective interest rate of the first and second drawdowns against the Teva Note, which take into consideration the beneficial conversion features and the right-to-borrow discounts, is 13.9% and 9.9%, respectively.
	In March 2014, we drew down an additional $5,000,000 against the Teva Note. At the time of the third drawdown, the contractual conversion price was less than the value of our common stock. As a result, we calculated the value of the beneficial conversion feature of the convertible note and recorded an increase to additional paid-in-capital and a discount on the Teva Note of $883,000 which will be amortized to interest expense over the remaining life of the borrowing. Additionally, we reclassified the relative portion of the unamortized right-to-borrow (see Note 9) against the Teva Note in the amount of $318,000 which will also be amortized to interest expense over the life of the borrowing. The effective interest rate of the third drawdown against the Teva Note, which takes into consideration the beneficial conversion features and the right-to-borrow discounts, is 11.6%.
	In June 2014, we drew down the remaining $5,000,000 against the Teva Note. At the time of the fourth drawdown, the contractual conversion price was less than the value of our common stock. As a result, we calculated the value of the beneficial conversion feature of the convertible note and recorded an increase to additional paid-in-capital and a discount on the Teva Note of $148,000 which will be amortized to interest expense over the remaining life of the borrowing. Additionally, we reclassified the relative portion of the unamortized right-to-borrow (see Note 9) against the Teva Note in the amount of $252,000, which will also be amortized to interest expense over the life of the borrowing. The effective interest rate of the fourth drawdown against the Teva Note, which takes into consideration the beneficial conversion features and the right-to-borrow discounts, is 6.6%.
	Royalty Securitization Financing
	In March 2014, we completed a royalty securitization financing, which consisted of a private placement to qualified institutional investors of $45,000,000 of non-recourse notes issued by our wholly-owned subsidiary, or the Notes, and warrants to purchase 345,661 shares of our common stock at a price of $0.01 per share exercisable for five years from the date of issuance. The Notes bear interest at 12.25% per annum payable quarterly beginning June 15, 2014. All royalty and milestone payments under the Teva Agreement, after paying interest, administrative fees, and any applicable taxes, will be applied to principal and interest payments on the Notes until the Notes have been paid in full.
	From the proceeds of the transaction, we established a $6,890,000 interest reserve account, which is classified as a noncurrent asset, to cover any potential shortfall in interest payments. Any remaining amounts in the interest reserve account will be released to us commencing June 15, 2015, subject to meeting certain net sales targets for ADASUVE, or, if not previously released, on December 15, 2015, irrespective of ADASUVE net sales. At June 30, 2014, $5,562,000 remained in the interest reserve account.
	The Notes are secured by the right to receive royalty and milestone payments under the Teva Agreement and our equity ownership in the wholly-owned subsidiary. The Notes have no other recourse to us. The Notes may not be redeemed at our option until after March 18, 2016, and may be redeemed after that date subject to the achievement of certain milestones and the payment of a redemption premium for any redemption occurring prior to March 19, 2019. The Notes are not convertible into Alexza equity, nor have we guaranteed them.
	We valued the warrants issued to the debt holders utilizing the Black-Scholes valuation model with an assumed volatility of 87%, an estimated life of 5 years, a 1.54% risk-free interest rate and a dividend rate of 0%. The total value of the warrants, $1,721,000, was recognized as an increase to Additional Paid In Capital and as a discount to the Notes. The amount will be amortized into interest expense over a five-year period. We incurred total fees and expenses of $4,171,000, which we recorded as a noncurrent Other Asset, and are amortizing into interest expense over a five-year period.
	Future Scheduled Payments
	Future scheduled principal payments under the debt obligations as of June 30, 2014 are as follows (in thousands):
		Total
	2014 - remaining 6 months		398
	2015		—
	2016		—
	2017		—
	2018		25,000
	Thereafter		—
	Total	$	25,398
	The above table excludes any payments pursuant to the $45,000,000 from the royalty securitization financing notes of our wholly-owned subsidiary, which have a legal maturity date in 2027. The principal payments by the subsidiary under the royalty securitization financing will be dependent upon the timing and amounts of royalties and milestone payments received under the Teva Agreement.

Facility_Leases

Facility Leases	6 Months Ended
	Jun. 30, 2014
Leases [Abstract]	'
Facility Leases	'
	8. Facility Leases
	We lease a building in Mountain View, California, which we began to occupy in the fourth quarter of 2007. We recognize rental expense on a straight-line basis over the initial term of the lease. Differences between the straight line rent expense and rent payments are classified as deferred rent liability on the balance sheet. The lease for the building expires on March 31, 2018, and we have two options to extend the lease for five years each.

License_Agreements

License Agreements	6 Months Ended
	Jun. 30, 2014
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
License Agreements	'
	9. License Agreements
	Grupo Ferrer Internacional, S.A.
	On October 5, 2011, we and Ferrer entered into the Ferrer Agreement to commercialize ADASUVE in the Ferrer Territories. Under the terms of the Ferrer Agreement, we received an upfront cash payment of $10,000,000, of which $5,000,000 was paid to the former stockholders of Allegro. The Ferrer Agreement provided for up to an additional $51,000,000 in additional milestone payments, contingent on approval of the EU Marketing Authorization Application, or MAA, certain individual country commercial sales initiations and royalty payments based on cumulative net sales targets in the Ferrer Territories. We are responsible for the MAA for ADASUVE. The MAA was submitted to the European Medicines Agency, or EMA, and was approved in February 2013 by the European Commission, or EC. We are also responsible for all post-authorization clinical studies required by the EMA and EC. Ferrer is responsible for the satisfaction of all other regulatory and pricing requirements to market and sell ADASUVE in the Ferrer Territories. Ferrer has the exclusive rights to commercialize the product in the Ferrer Territories. We supply ADASUVE to Ferrer for all of its commercial sales, and receive a specified per-unit transfer price paid in Euros. Either party may terminate the Ferrer Agreement for the other party’s uncured material breach or bankruptcy. The Ferrer Agreement continues in effect on a country-by-country basis until the later of the last to expire patent covering ADASUVE in such country or 12 years after first commercial sale. The Ferrer Agreement is subject to earlier termination in the event the parties mutually agree, by a party in the event of an uncured material breach by the other party or upon the bankruptcy or insolvency of either party.
	In March 2012, we entered into an amendment to the Ferrer Agreement. We and Ferrer agreed to eliminate the potential MAA approval milestone payment in exchange for Ferrer’s purchase of 241,936 shares of our common stock for $12.40 per share for a total of $3,000,000, which reflected a premium on the fair value of our common stock of approximately $1,452,000 at the time of the transaction.
	We evaluated whether the delivered elements under the Ferrer Agreement have value on a stand-alone basis and allocated revenue to the identified units of accounting based on relative fair value. We determined that the license and the development and regulatory services are a single unit of accounting as the licenses were determined not to have stand-alone value. We have begun to deliver all elements of the arrangement and are recognizing the $10,000,000 upfront payment as revenue ratably over the estimated performance period of the agreement of four years. The $1,452,000 premium received from the sale of common stock to Ferrer is additional consideration received pursuant to the Ferrer Agreement and does not pertain to a separate deliverable or element of the arrangement, and thus is being deferred and recognized as revenue in a manner consistent with the $10,000,000 upfront payment. We recognized revenue related to the amortization of the upfront payment and premium of $364,000 and $1,093,000 during the three and months ended June 30, 2014, respectively and $729,000 and $1,093,000 of revenue in the same periods in 2013, respectively. As of June 30, 2014, we had deferred revenue of $4,008,000 related to the upfront payment and premium received.
	The Ferrer Agreement, as amended, provides for us to receive up to $48,000,000 of additional payments related to first commercial sales in nine identified countries and cumulative net sales targets in the Ferrer Territories. The cumulative net sales targets will be recognized as royalty revenue when each target is earned and payable to us. The first commercial sales payments in the nine identified countries were or will be recognized utilizing the milestone method of revenue recognition. We believe each of these milestones is substantive as there is uncertainty that the milestones will be met, the milestone can only be achieved as a result of our past performance and the achievement of the milestone will result in additional payment to us. We will recognize milestone revenue upon first commercial sales in each of these identified countries. In 2013, we received and recognized revenue on the first milestone in the amount of $1,250,000, for the first product sale in Germany, of which $312,500 was paid to the former stockholders of Allegro (see Note 3). In January 2014, we recognized revenue in the amount of $1,000,000 from a milestone payment for the first product sale in Spain, of which $250,000 was paid to the former stockholders of Allegro (see Note 3).
	Teva Pharmaceuticals USA, Inc.
	In May 2013, we entered into the Teva Agreement to provide Teva with an exclusive license to develop and commercialize ADASUVE in the United States. Under the terms of the Teva Agreement, Teva is responsible for all U.S. development, regulatory and commercialization activities for ADASUVE, including the U.S. post-approval clinical studies and any additional clinical trials for new indications. Teva has the full right to sublicense its rights and obligations under the Teva Agreement. We are responsible for manufacturing and supplying ADASUVE to Teva for clinical trials and commercial sales. Teva has the exclusive rights to commercialize ADASUVE and AZ-104 in the United States and the co-exclusive rights, with us and our affiliates, to manufacture the product.
	In May 2013, we received an upfront cash payment of $40,000,000 from Teva, $10,000,000 of which was paid to the former stockholders of Allegro. We are eligible to receive up to $195,000,000 in additional payments contingent on Teva’s successful completion of the ADASUVE post-approval studies in the United States and Teva achieving specified net sales targets. In addition to these payments, we supply ADASUVE to Teva for all of its clinical trials and commercial sales, and we receive a specified per-unit transfer price in an amount of the greater of our costs of commercial production or a specified per-unit price. Teva makes tiered royalty payments based on net commercial sales of ADASUVE in the United States. In March 2014, Teva announced the U.S. launch of ADASUVE. In March 2014, we completed a royalty securitization financing, in which we transferred certain rights to U.S. royalty and milestone payments under the Teva Agreement to a wholly-owned subsidiary. The subsidiary then sold $45,000,000 in notes backed by the royalty and milestone payments in a private placement to institutional accredited investors. The notes have no recourse to us, other than to our equity interest in our wholly-owned subsidiary, and we did not guarantee the notes.
	Unless earlier terminated, the Teva Agreement continues in effect until the later of the last to expire patent covering ADASUVE in the United States or a specified number of years after first commercial sale. The Agreement is subject to earlier termination in the event the parties mutually agree, by a party in the event of an uncured material breach by the other party or upon the bankruptcy or insolvency of either party. Teva may also terminate the Teva Agreement in the event the U.S. Food and Drug Administration requires withdrawal or suspension of ADASUVE from the market due to safety reasons or, subject to a specified period of notice, for Teva’s convenience at any time following the first anniversary of the Teva Agreement.
	We evaluated whether the delivered elements under the Teva Agreement have value on a stand-alone basis and allocated revenue to the identified units of accounting based on relative fair value. We determined that the license fees are a single unit of accounting and valued the license based on its best estimate of selling price, as VSOE and TPE of the selling price could not be determined. The selling price was estimated using discounted projected cash flows related to the licensed territory. We have delivered the license to Teva and recognized the $40,000,000 non-refundable upfront payment as revenue during the third quarter ended June 30, 2013.
	As described in Note 7, in connection with the Teva Agreement, we received a right-to-borrow under the Teva Note. We have the ability to draw on the Teva Note in amounts not to exceed $25,000,000, over a two year period. As outlined in Note 7, the Teva Note has a fixed conversion price and interest rate. This right-to-borrow was considered additional consideration provided by Teva to us pursuant to the Teva Agreement. We performed an analysis using a Monte Carlo simulation model with a volatility rate of 70% and an estimated debt yield of 15%. Based on this analysis, we determined that the fair value of this right-to-borrow was $2,800,000. We recognized this amount as revenue and as another asset upon entering into the Teva Note during the quarter ended June 30, 2013. The asset is being amortized to interest expense over the two year period during which we are able to exercise the right-to-borrow. As we draw on the Teva Note, the relative portion of the unamortized right-to-borrow is accounted for as a discount on the borrowing and will be amortized to interest expense over the life of the borrowing. As of June 30, 2014, we have drawn down the full $25,000,000.
	As noted above, we are eligible to receive up to $195,000,000 of additional payments from Teva related to Teva’s successful completion of the ADASUVE post-approval studies in the United States and Teva achieving specified net sales targets. The payments related to net sales targets will be recognized as royalty revenue when each target is earned and payable to us. The payment related to the completion of the ADASUVE post-approval studies will be recognized upon completion of the studies when the payment is earned and payable to us.

Autoliv_Manufacturing_and_Supp

Autoliv Manufacturing and Supply Agreement	6 Months Ended
	Jun. 30, 2014
Commitments And Contingencies Disclosure [Abstract]	'
Autoliv Manufacturing and Supply Agreement	'
	10. Autoliv Manufacturing and Supply Agreement
	In November 2007, we entered into a Manufacturing and Supply Agreement, or the Manufacture Agreement, with Autoliv relating to the commercial supply of chemical heat packages that can be incorporated into our Staccato device, or the Chemical Heat Packages. Autoliv had developed these Chemical Heat Packages for us pursuant to a development agreement between Autoliv and us. Under the terms of the Manufacture Agreement, Autoliv agreed to develop a manufacturing line capable of producing 10 million Chemical Heat Packages a year.
	In June 2010 and February 2011, we entered into agreements to amend the terms of the Manufacture Agreement, or together the Amendments. Under the terms of the first Amendment, we paid Autoliv $4,000,000 and issued Autoliv a $4,000,000 unsecured promissory note in return for a production line for the commercial manufacture of Chemical Heat Packages. Each production line is comprised of two identical and self-sustaining “cells,” and the first such cell was completed, installed and qualified in connection with such Amendment. Under the terms of the second Amendment, the original $4,000,000 note was cancelled and the New Note was issued with a reduced principal amount of $2,800,000, and production on the second cell ceased. The New Note is payable in 48 equal monthly installments of approximately $68,000.
	Subject to certain exceptions, Autoliv has agreed to manufacture, assemble and test the Chemical Heat Packages solely for us in conformance with our specifications. We pay Autoliv a specified purchase price, which varies based on annual quantities we order, per Chemical Heat Package delivered. In October 2013, Autoliv notified us of their intent to terminate, effective October 2016, the Manufacture Agreement. Prior to October 2016, we and Autoliv remain fully obligated to perform pursuant to the terms of both the Manufacture Agreement and the New Note. The Manufacture Agreement provides that during the term of the Manufacture Agreement, Autoliv will be our exclusive supplier of the Chemical Heat Packages. In addition, the Manufacture Agreement grants Autoliv the right to negotiate for the right to supply commercially any second generation Chemical Heat Package, or a Second Generation Product, and provides that we will pay Autoliv certain royalty payments if we manufacture Second Generation Products ourselves or if we obtain Second Generation Products from a third party manufacturer. Upon the termination of the Manufacture Agreement, we will be required, on an ongoing basis, to pay Autoliv certain royalty payments related to the manufacture of the Chemical Heat Packages by us or third-party manufacturers.
	In April 2014, we contracted with Autoliv, through a third-party supplier, to build two additional manufacturing cells at a cost of approximately $2.1 million for each cell. We plan for one of the additional cells to be utilized for additional capacity to meet our projected manufacturing volume and one cell is planned to be utilized by our replacement heat package manufacturer. Once our agreement with Autoliv concludes, the two cells at Autoliv will be moved to our replacement heat package manufacturer.

The_Company_and_Basis_of_Prese1

The Company and Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 8-03 of Regulation S-X. Accordingly, they do not contain all of the information and footnotes required for complete financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly our interim condensed consolidated financial information. The results for the three and six months ended June 30, 2014 are not necessarily indicative of the results to be expected for the year ending December 31, 2014 or for any other interim period or any other future year.
	The accompanying unaudited condensed consolidated financial statements and notes to condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2013 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 25, 2014.
Basis of Consolidation	'
	Basis of Consolidation
	The unaudited condensed consolidated financial statements include our accounts and those of our wholly-owned subsidiaries. All significant intercompany balances and transactions have been eliminated.
Revenue Recognition	'
	Revenue Recognition
	We recognize revenue when (i) persuasive evidence of an arrangement exists; (ii) delivery has occurred or services have been rendered; (iii) the fee is fixed or determinable; and (iv) collectability is reasonably assured. Prior to the second quarter of 2013, our revenue consisted primarily of amounts earned from collaboration agreements and under research grants with the National Institutes of Health. Beginning in the second quarter of 2013, we also have revenue from product sales.
	For collaboration agreements, revenues for non-refundable upfront license fee payments, where we continue to have performance obligations, are recognized as performance occurs and obligations are completed. Revenues for non-refundable upfront license fee payments where we do not have significant future performance obligations are recognized when the agreement is signed and the payments are due.
	For multiple element arrangements, such as collaboration agreements in which a collaborator may purchase several deliverables, we account for each deliverable as a separate unit of accounting if both of the following criteria are met: (i) the delivered item or items have value to the customer on a standalone basis; and (ii) for an arrangement that includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in our control. We evaluate how the consideration should be allocated among the units of accounting and allocate revenue to each non-contingent element based upon the relative selling price of each element. We determine the relative selling price for each deliverable using (i) vendor-specific objective evidence, or VSOE, of selling price if it exists; (ii) third-party evidence, or TPE, of selling price if it exists; or (iii) our best estimated selling price for that deliverable if neither VSOE nor TPE of selling price exists for that deliverable. We then recognize the revenue allocated to each element when the four basic revenue criteria described above are met for each element.
	For milestone payments received in connection with our collaboration agreements, we have elected to adopt the milestone method of accounting under Financial Accounting Standards Board Accounting Standards Codification 605-28, Milestone Method. Under the milestone method, revenues for payments which meet the definition of a milestone will be recognized as the respective milestones are achieved.
	We recognize product revenue as follows:
		•	Persuasive Evidence of an Arrangement. We currently sell product through license and supply agreements with our collaborators, Grupo Ferrer Internacional, S.A., or Ferrer, and Teva Pharmaceuticals USA, Inc., or Teva. Persuasive evidence of an arrangement is generally determined by the receipt of an approved purchase order from the collaborator in connection with the terms of the related license and supply agreements.
		•	Delivery. Typically, ownership of the product passes to the collaborator upon shipment. Our current license and supply agreements also provide our collaborators with an acceptance period during which they may reject any product which does not conform to agreed-upon specifications. Because ADASUVE is a new product, a new technology and our first product to be commercialized, and because we do not have a history of producing product to collaborator specifications, we will not consider delivery to have occurred until after the collaborator acceptance period has ended or the collaborator has positively accepted the product. Once we have demonstrated over the course of time an ability to reliably produce the product to collaborator specifications, we will consider delivery to have occurred upon shipment in the absence of any other relevant shipment or acceptance terms.
		•	Sales Price Fixed or Determinable. Sales prices for product shipments are determined by license and supply agreements and documented in purchase orders. After the collaborator acceptance period has ended or the collaborator has positively accepted the product, our collaborators do not have any product return or replacement rights, including for expired products.
		•	Collectability. Payment for the product is contractually obligated under the license and supply agreements. We will monitor payment histories for our collaborators and specific issues as they arise to determine whether collection is probable for a specific transaction and defer revenue as necessary.
	Royalty revenue from our collaboration agreements will be recognized as we receive information from our collaborators regarding product sales and collectability is reasonably assured.
	Significant management judgment is used in the determination of revenue to be recognized and the period in which it is recognized.
Inventory	'
	Inventory
	Inventory is stated at standard cost, which approximates actual cost, determined on a first-in first-out basis, not in excess of market value. Inventory includes the direct costs incurred to manufacture products combined with allocated manufacturing overhead, which consists of indirect costs, including labor and facility overhead. We are in the early stages of commercialization and have incurred significantly higher than normal indirect costs in the production of our inventory due to start-up manufacturing costs and low production volumes. The carrying cost of inventory is reduced so as to not be in excess of the market value of the inventory as determined by the contractual transfer prices to Ferrer and Teva. The excess over the market value is expensed to cost of goods sold. All costs associated with the ADASUVE manufacturing process incurred prior to regulatory approval and the beginning of commercial manufacturing were expensed as a component of research and development expense. If information becomes available that suggests that all or certain of the inventory may not be realizable, we may be required to expense a portion, or all, of the capitalized inventory into cost of goods sold.
New Accounting Pronouncement	'
	New Accounting Pronouncement
	In May 2014 the Financial Accounting Standards Board, or (FASB, issued the Accounting Standards Update, or ASU, No. 2014-09, Revenue from Contracts with Customers (Topic 606), that will supersede nearly all existing revenue recognition guidance under US GAAP. The core principle of the guidance is that an entity should recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. The standard will be effective for public entities for annual and interim periods beginning after December 15, 2016.
	Entities can choose to apply the standard using either the full retrospective approach or a modified retrospective approach. Entities electing the full retrospective adoption will apply the standard to each period presented in the financial statements. This means that entities will have to apply the new guidance as if it had been in effect since the inception of all its contracts with customers presented in the financial statements. Entities that elect the modified retrospective approach will apply the guidance retrospectively only to the most current period presented in the financial statements. This means that entities will have to recognize the cumulative effect of initially applying the new standard as an adjustment to the opening balance of retained earnings at the date of initial application. The new revenue standard will be applied to contracts that are in progress at the date of initial application.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2014
Accounting Policies [Abstract]	'
Schedule of Inventory	'
	Inventory, which is stated at the lower of cost or estimated market value, consists of the following at June 30, 2014 and December 31, 2013 (in thousands):
		June 30,		December 31,
		2014		2013
	Raw materials	$	3,857	$	3,044
	Work in process		117		—
	Finished goods		—		403
	Total inventory	$	3,974	$	3,447

Fair_Value_Accounting_Tables

Fair Value Accounting (Tables)	6 Months Ended
	Jun. 30, 2014
Fair Value Disclosures [Abstract]	'
Financial Assets by Major Security Type and Liability Measured at Fair Value on Recurring Basis	'
	The following table represents the fair value hierarchy for our financial assets (cash equivalents and marketable securities) by major security type and contingent consideration liability measured at fair value on a recurring basis as of June 30, 2014 and December 31, 2013 (in thousands):
	June 30, 2014	Level 1			Level 2			Level 3			Total
	Assets
	Money market funds	$	10,917		$	—		$	—		$	10,917
	Corporate debt securities		—			38,023			—			38,023
	Total assets	$	10,917		$	38,023		$	—		$	48,940
	Liabilities
	Contingent consideration liability	$	—		$	—		$	32,500		$	32,500
	Total liabilities	$	—		$	—		$	32,500		$	32,500
	December 31, 2013	Level 1			Level 2			Level 3			Total
	Assets
	Money market funds	$	11,345		$	—		$	—		$	11,345
	Corporate debt securities		—			12,003			—			12,003
	Total assets	$	11,345		$	12,003		$	—		$	23,348
	Liabilities
	Contingent consideration liability	$	—		$	—		$	39,200		$	39,200
	Total liabilities	$	—		$	—		$	39,200		$	39,200
Schedule of Cash Equivalents and Marketable Securities	'
	The amortized cost, fair value and unrealized gain/(loss) for our financial assets by major security type as of June 30, 2014 and December 31, 2013 are as follows (in thousands):
	June 30, 2014	Amortized			Fair Value			Unrealized
		Cost						Gain/(Loss)
	Money market funds	$	10,917		$	10,917		$	—
	Corporate debt securities		38,021			38,023			2
	Total		48,938			48,940			2
	Less amounts classified as restricted cash		(5,562	)		(5,562	)
	Less amounts classified as cash equivalents		(10,294	)		(10,294	)		—
	Total marketable securities	$	33,082		$	33,084		$	2
	December 31, 2013	Amortized			Fair Value			Unrealized
		Cost						Gain/(Loss)
	Money market funds	$	11,345		$	11,345		$	—
	Corporate debt securities		12,002			12,003			1
	Total		23,347			23,348			1
	Less amounts classified as cash equivalents		(14,770	)		(14,770	)		—
	Total marketable securities	$	8,577		$	8,578		$	1
Fair Value Measurement of Contingent Consideration Liability	'
	The following table represents a reconciliation of the change in the fair value measurement of the contingent consideration liability for the three and six months ended June 30, 2014 and 2013 (in thousands):
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Beginning balance	$	40,100		$	9,600		$	39,200		$	9,600
	Payments made		(1	)		—			(251	)		—
	Adjustments to fair value measurement		(7,599	)		10,900			(6,449	)		10,900
	Ending balance	$	32,500		$	20,500		$	32,500		$	20,500

ShareBased_Compensation_Plans_

Share-Based Compensation Plans (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Summary of Option Activity under Company's Share-Based Compensation Plans	'
	The following table sets forth the summary of option activity under our share-based compensation plans for the six months ended June 30, 2014:
		Outstanding Options
		Number of			Weighted
		Shares			Average
					Exercise Price
	Outstanding at January 1, 2014		2,121,504		$	7.53
	Options granted		999,200			4.81
	Options exercised		(18,768	)		3.47
	Options canceled		(244,023	)		5.76
	Outstanding at June 30, 2014		2,857,913			6.76
Summary of Restricted Stock Unit Activity under Company's Share-Based Compensation Plans	'
	The following table sets forth the summary of restricted stock unit activity under our share-based compensation plans for the six months ended June 30, 2014:
		Number			Weighted
		Of			Average
		Shares			Grant-Date
					Fair Value
	Outstanding at January 1, 2014		521,050		$	4.68
	Granted		—			—
	Released		(31,825	)		4.68
	Forfeited		(95,750	)		4.68
	Outstanding at June 30, 2014		393,475		$	4.68

ShareBased_Compensation_Tables

Share-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Weighted Average Fair Value of Employee Stock Options Granted	'
	During the three and six months ended June 30, 2014 and 2013, the per share weighted average fair value of employee stock options granted were as follows:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Stock options	$	2.95		$	3.47		$	3.2		$	3.46
	Restricted stock units		—			4.68			—			4.67
	Stock purchase rights		1.48			1.41			1.48			1.53
Estimated Grant Date Fair Values of Stock Options with Weighted Average Assumptions	'
	The estimated grant date fair values of the stock options and stock purchase rights were calculated using the Black-Scholes valuation model, and the following weighted average assumptions:
		Three Months Ended						Six Months Ended
		June 30,						June 30,
		2014			2013			2014			2013
	Stock Option Plans
	Expected term		5.0 years			5.0 years			5.0 years			5.0 years
	Expected volatility		82	%		100	%		84	%		100	%
	Risk-free interest rate		1.65	%		0.84	%		1.61	%		0.77	%
	Dividend yield		0	%		0	%		0	%		0	%
	Employee Stock Purchase Plan
	Expected term		0.5 years			0.5 years			0.5 years			0.5 years
	Expected volatility		61	%		63	%		61	%		70	%
	Risk-free interest rate		0.67	%		0.12	%		0.67	%		0.13	%
	Dividend yield		0	%		0	%		0	%		0	%

Net_Loss_per_Share_Tables

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2014
Earnings Per Share [Abstract]	'
Anti-Dilutive Securities Excluded from Net Loss per Share	'
	The following items were excluded from the net loss per share calculation for the three and six months ended June 30, 2014 and 2013 because the inclusion of such items would have had an anti-dilutive effect:
		Three Months Ended				Six Months Ended
		June 30,				June 30,
		2014		2013		2014		2013
	Stock options		2,584,615		1,526,083		2,430,244		1,363,470
	Restricted stock units		435,388		263,475		463,942		175,650
	Warrants to purchase common stock		6,807,727		6,462,066		6,692,507		6,462,066
	Convertible debt		4,951,459		—		4,416,222		—

Financing_Obligations_Tables

Financing Obligations (Tables)	6 Months Ended
	Jun. 30, 2014
Debt Disclosure [Abstract]	'
Long Term Debt Payments by Year	'
	Future scheduled principal payments under the debt obligations as of June 30, 2014 are as follows (in thousands):
		Total
	2014 - remaining 6 months		398
	2015		—
	2016		—
	2017		—
	2018		25,000
	Thereafter		—
	Total	$	25,398

The_Company_and_Basis_of_Prese2

The Company and Basis of Presentation - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014
	Segment
Organization Consolidation And Presentation Of Financial Statements [Abstract]	'
Number of business segment	1

Summary_of_Significant_Account2

Summary of Significant Accounting Policies - Schedule of Inventory (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$3,857	$3,044
Work in process	117	0
Finished goods	0	403
Total inventory	$3,974	$3,447	[1]
[1]	The condensed consolidated balance sheet at December 31, 2013 has been derived from audited consolidated financial statements at that date.

Fair_Value_Accounting_Financia

Fair Value Accounting - Financial Assets by Major Security Type and Liability Measured at Fair Value on Recurring Basis (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$10,294	$14,770
Total assets	48,940	23,348
Liabilities	'	'
Contingent consideration liability	32,500	39,200
Total liabilities	32,500	39,200
Money market funds [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	10,917	11,345
Corporate debt securities [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	38,023	12,003
Level 1 [Member]	'	'
Assets	'	'
Total assets	10,917	11,345
Liabilities	'	'
Contingent consideration liability	0	0
Total liabilities	0	0
Level 1 [Member] | Money market funds [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	10,917	11,345
Level 1 [Member] | Corporate debt securities [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Level 2 [Member]	'	'
Assets	'	'
Total assets	38,023	12,003
Liabilities	'	'
Contingent consideration liability	0	0
Total liabilities	0	0
Level 2 [Member] | Money market funds [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Level 2 [Member] | Corporate debt securities [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	38,023	12,003
Level 3 [Member]	'	'
Assets	'	'
Total assets	0	0
Liabilities	'	'
Contingent consideration liability	32,500	39,200
Total liabilities	32,500	39,200
Level 3 [Member] | Money market funds [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	0	0
Level 3 [Member] | Corporate debt securities [Member]	'	'
Assets	'	'
Cash and Cash Equivalents, Fair Value Disclosure	$0	$0

Fair_Value_Accounting_Schedule

Fair Value Accounting - Schedule of Cash Equivalents and Marketable Securities (Detail) (USD $)	Jun. 30, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Cash Cash Equivalents And Investments [Line Items]	'	'
Amortized Cost	$33,082	$8,577
Fair Value	33,084	8,578	[1]
Unrealized Gain/(Loss)	2	1
Less amounts classified as restricted cash, Amortized Cost	-5,562	'
Less amounts classified as restricted cash, Fair Value	-5,562	'
Less amounts classified as cash equivalents, Amortized Cost	-10,294	-14,770
Less amounts classified as cash equivalents, Fair Value	-10,294	-14,770
Less amounts classified as cash equivalents, Unrealized Gain/(Loss)	0	0
Money market funds [Member]	'	'
Cash Cash Equivalents And Investments [Line Items]	'	'
Amortized Cost	10,917	11,345
Fair Value	10,917	11,345
Unrealized Gain/(Loss)	0	0
Less amounts classified as cash equivalents, Fair Value	-10,917	-11,345
Corporate debt securities [Member]	'	'
Cash Cash Equivalents And Investments [Line Items]	'	'
Amortized Cost	38,021	12,002
Fair Value	38,023	12,003
Unrealized Gain/(Loss)	2	1
Less amounts classified as cash equivalents, Fair Value	-38,023	-12,003
Total [Member]	'	'
Cash Cash Equivalents And Investments [Line Items]	'	'
Amortized Cost	48,938	23,347
Fair Value	48,940	23,348
Unrealized Gain/(Loss)	$2	$1
[1]	The condensed consolidated balance sheet at December 31, 2013 has been derived from audited consolidated financial statements at that date.

Fair_Value_Accounting_Addition

Fair Value Accounting - Additional Information (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'
Sales of marketable securities	$0	$0	$0	$0	'
Cash flow discount rate	'	'	16.50%	'	'
Increase (decrease) on change in fair value of contingent consideration liability	-7,599,000	31,500,000	-6,449,000	42,400,000	'
Increase (decrease) to the net loss, per share	($0.44)	$1.92	($0.37)	$2.64	'
Estimated fair value of financing obligations	56,135,000	'	56,135,000	'	9,342,000
Book value of financing obligations	$63,393,000	'	$63,393,000	'	$11,524,000
Minimum [Member]	'	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'
Change in percentage of WACC	'	16.50%	'	'	'
Maximum [Member]	'	'	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'	'	'
Change in percentage of WACC	'	18.00%	'	'	'

Fair_Value_Accounting_Fair_Val

Fair Value Accounting - Fair Value Measurement of Contingent Consideration Liability (Detail) (USD $)	3 Months Ended		6 Months Ended
In Thousands, unless otherwise specified	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Fair Value Disclosures [Abstract]	'	'	'	'
Beginning balance	$40,100	$9,600	$39,200	$9,600
Payments made	-1	0	-251	0
Adjustments to fair value measurement	-7,599	10,900	-6,449	10,900
Ending balance	$32,500	$20,500	$32,500	$20,500

ShareBased_Compensation_Plans_1

Share-Based Compensation Plans - Additional Information (Detail) (USD $)

3 Months Ended

6 Months Ended

12 Months Ended

12 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2005

Jun. 30, 2014

31-May-13

Dec. 31, 2005

Jun. 30, 2014

31-May-13

Jan. 31, 2014

Jan. 31, 2013

Jan. 31, 2014

Jan. 31, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Dec. 31, 2005

2005 Equity Incentive Plan [Member]

2005 Equity Incentive Plan [Member]

2005 Equity Incentive Plan [Member]

2005 Non-Employee Director's Stock Option Plan [Member]

2005 Non-Employee Director's Stock Option Plan [Member]

2005 Non-Employee Director's Stock Option Plan [Member]

Evergreen Provisions of 2005 Plan [Member]

Evergreen Provisions of 2005 Plan [Member]

Evergreen Provisions of Director's Plan [Member]

Evergreen Provisions of Director's Plan [Member]

2005 Employee Stock Purchase Plan [Member]

2005 Employee Stock Purchase Plan [Member]

2005 Employee Stock Purchase Plan [Member]

2005 Employee Stock Purchase Plan [Member]

2005 Employee Stock Purchase Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Effective date of Equity Incentive Plan 2005 and closing date of company's initial public offering

'

'

'

'

8-Mar-06

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Increase in annual reserve by percentage of shares of common stock

'

'

'

'

2.00%

'

'

'

'

'

'

'

'

'

'

'

1.00%

'

'

Increase in annual reserve by shares of common stock

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Vesting period for stock options and restricted stock units

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

'

'

'

Maximum contractual term for issuing new grants stock options and restricted stock units

'

'

'

'

'

'

'

'10 years

'

'

'

'

'

'

'

'

'

'

'

Intrinsic value of options exercised

$16,000

$0

$21,000

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Authorized shares of common stock for issuance, Number of Shares

'

'

'

'

'

'

'

'

'

'

100,000

100,000

58,751

19,812

'

'

75,000

'

'

Shares authorized for issuance include annual reserve

'

'

'

'

'

'

2,200,000

'

'

200,000

'

'

'

'

'

'

'

'

'

Shares available for issuance

'

'

'

'

'

465,969

'

'

150,000

'

'

'

'

'

'

'

'

'

'

Employees purchase common stock on their enrollment date

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

85.00%

Employee stock purchase plan fixed offering period

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'6 months

Shares issued under ESPP

'

'

'

'

'

'

'

'

'

'

'

'

'

'

37,096

18,843

37,096

18,843

'

Weighted average price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3.63

$3.65

$3.63

$3.65

'

Shares available for issuance under the ESPP

'

'

'

'

'

'

'

'

'

'

'

'

'

'

112,536

'

112,536

'

'

ShareBased_Compensation_Plans_2

Share-Based Compensation Plans - Summary of Option Activity under Company's Share-Based Compensation Plans (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]	'
Outstanding at January 1, 2014, Number of Shares	2,121,504
Options granted, Number of Shares	999,200
Options exercised, Number of Shares	-18,768
Options canceled, Number of Shares	-244,023
Outstanding at June 30, 2014, Number of Shares	2,857,913
Outstanding at January 1, 2014, Weighted Average Exercise Price	$7.53
Options granted, Weighted Average Exercise Price	$4.81
Options exercised, Weighted Average Exercise Price	$3.47
Options canceled, Weighted Average Exercise Price	$5.76
Outstanding at June 30, 2014 , Weighted Average Exercise Price	$6.76

ShareBased_Compensation_Plans_3

Share-Based Compensation Plans - Summary of Restricted Stock Unit Activity under Company's Share-Based Compensation Plans (Detail) (Restricted Stock Units [Member], USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Restricted Stock Units [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Outstanding at January 1, 2014, Number Of Shares	'	'	521,050	'
Granted, Number Of Shares	'	'	0	'
Released, Number Of Shares	'	'	-31,825	'
Forfeited, Number Of Shares	'	'	-95,750	'
Outstanding at June 30, 2014, Number Of Shares	393,475	'	393,475	'
Outstanding at January 1, 2014, Weighted Average Grant-Date Fair Value	'	'	$4.68	'
Granted, Weighted Average Grant-Date Fair Value	$0	$4.68	$0	$4.67
Released, Weighted Average Grant-Date Fair Value	'	'	$4.68	'
Forfeited, Weighted Average Grant-Date Fair Value	'	'	$4.68	'
Outstanding at June 30, 2014, Weighted Average Grant-Date Fair Value	$4.68	'	$4.68	'

ShareBased_Compensation_Weight

Share-Based Compensation - Weighted Average Fair Value of Employee Stock Options Granted (Detail) (USD $)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock options	$2.95	$3.47	$3.20	$3.46
Restricted Stock Units [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock units	$0	$4.68	$0	$4.67
Stock Purchase Rights [Member] | Employee Stock Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Stock units	$1.48	$1.41	$1.48	$1.53

ShareBased_Compensation_Estima

Share-Based Compensation - Estimated Grant Date Fair Values of Stock Options with Weighted Average Assumptions (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock options [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected term	'5 years	'5 years	'5 years	'5 years
Expected volatility	82.00%	100.00%	84.00%	100.00%
Risk-free interest rate	1.65%	0.84%	1.61%	0.77%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Employee Stock Purchase Plan [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Expected term	'6 months	'6 months	'6 months	'6 months
Expected volatility	61.00%	63.00%	61.00%	70.00%
Risk-free interest rate	0.67%	0.12%	0.67%	0.13%
Dividend yield	0.00%	0.00%	0.00%	0.00%

ShareBased_Compensation_Additi

Share-Based Compensation - Additional Information (Detail) (USD $)	6 Months Ended
	Jun. 30, 2014
Employee Stock Purchase Plan [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Total unrecognized compensation expense related to unvested stock option awards	$44,000
Expenses expected to be recognized over a weighted average period	'3 months 18 days
Restricted Stock Units [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Dividends will be paid prior to the vesting of the restricted stock unit	0
Unvested stock option awards [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Total unrecognized compensation expense	5,321,000
Expenses expected to be recognized over a weighted average period	'2 years 7 months 6 days
Unvested restricted stock units [Member]	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'
Total unrecognized compensation expense	$1,328,000
Expenses expected to be recognized over a weighted average period	'2 years 4 months 24 days

Net_Loss_per_Share_AntiDilutiv

Net Loss per Share - Anti-Dilutive Securities Excluded from Net Loss per Share (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2014	Jun. 30, 2013
Stock options [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	2,584,615	1,526,083	2,430,244	1,363,470
Restricted Stock Units [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	435,388	263,475	463,942	175,650
Warrants to purchase common stock [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	6,807,727	6,462,066	6,692,507	6,462,066
Convertible debt [Member]	'	'	'	'
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]	'	'	'	'
Anti-dilutive securities	4,951,459	0	4,416,222	0

Financing_Obligations_Addition

Financing Obligations - Additional Information (Detail) (USD $)

1 Months Ended

6 Months Ended

1 Months Ended

3 Months Ended

6 Months Ended

12 Months Ended

1 Months Ended

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2013

Feb. 28, 2011

Jun. 30, 2010

Jun. 30, 2014

Mar. 31, 2014

31-May-13

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2014

Dec. 31, 2013

Feb. 28, 2011

Jun. 30, 2010

Feb. 28, 2011

Autoliv ASP, Inc. [Member]

Autoliv ASP, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Original Note [Member]

Original Note [Member]

New Note [Member]

Autoliv ASP, Inc. [Member]

Autoliv ASP, Inc. [Member]

Autoliv ASP, Inc. [Member]

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Amount of cash paid to Autoliv ASP, Inc.

'

'

'

'

$4,000,000

'

'

'

'

'

'

'

'

'

'

Value of unsecured promissory note issued

'

'

'

'

'

'

'

'

'

'

'

'

4,000,000

4,000,000

2,800,000

Value of cancelled note

'

'

'

4,000,000

'

'

'

'

'

'

'

'

'

'

4,000,000

Debt instrument interest rate

'

'

'

'

'

'

'

4.00%

'

'

'

'

'

'

8.00%

Installment period of New Note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'48 months

Periodic payment of New Note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

68,000

Aggregate term loan advances

'

'

'

'

'

'

'

25,000,000

'

'

'

'

'

'

'

Debt instrument payment terms

'

'

'

'

'

'

'

'

'

'

'We may prepay, from time to time, up to one-half of the total amounts advanced plus the related interest outstanding at any time prior to the maturity date. At any time prior to five days before the maturity date, Teva will have the right to convert the then outstanding amounts into shares of our common stock at a conversion price of $4.4833 per share.

'

'

'

'

Debt instrument conversion price per share

'

'

'

'

'

'

'

$4.48

'

'

'

'

'

'

'

Number of years from effective date to receive note advances

'

'

'

'

'

'

'

'2 years

'

'

'

'

'

'

'

Borrowing under loan agreement

'

50,830,000

0

'

'

5,000,000

5,000,000

'

5,000,000

10,000,000

'

15,000,000

'

'

'

Unamortized discount from financing obligation

'

1,032,000

0

'

'

148,000

883,000

'

3,112,000

'

148,000

3,112,000

'

'

'

Unamortized borrowing cost from financing obligation

'

'

'

'

'

252,000

318,000

'

1,293,000

'

252,000

1,293,000

'

'

'

Effective interest rate of notes

12.25%

'

'

'

'

6.60%

11.60%

'

9.90%

13.90%

6.60%

9.90%

'

'

'

Non-recourse notes issued

45,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrants to purchase common stock

345,661

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Price of common stock per share

$0.01

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Warrant exercisable term

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

First quarterly interest payment

'

15-Jun-14

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest reserve

6,890,000

5,562,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest reserve description

'

'Any remaining amounts in the interest reserve account will be released to us commencing June 15, 2015, subject to meeting certain net sales targets for ADASUVE, or, if not previously released, on December 15, 2015, irrespective of ADASUVE net sales.

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes redemption description

'

'The Notes have no other recourse to us. The Notes may not be redeemed at our option until after March 18, 2016, and may be redeemed after that date subject to the achievement of certain milestones and the payment of a redemption premium for any redemption occurring prior to March 19, 2019.

'

'

'

'

'

'

'

'

'

'

'

'

'

Estimated life of the warrant

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected volatility rate

'

87.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Risk-free interest rate

'

1.54%

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected dividend yield

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

Interest expense amortization period

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

Total value of warrants

'

1,721,000

0

'

'

'

'

'

'

'

'

'

'

'

'

Total fees and expenses

'

4,171,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Financing from royalty securitization

'

$45,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty securitization financing legal maturity date

'

'2027

'

'

'

'

'

'

'

'

'

'

'

'

'

Financing_Obligations_Long_Ter

Financing Obligations - Long Term Debt Payments by Year (Detail) (USD $)	Jun. 30, 2014
In Thousands, unless otherwise specified
Debt Disclosure [Abstract]	'
2014 - remaining 6 months	$398
2015	0
2016	0
2017	0
2018	25,000
Thereafter	0
Total	$25,398

Facility_Leases_Additional_Inf

Facility Leases - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2014
	Lease
Leases [Abstract]	'
Expiry of lease of Building	31-Mar-18
Operating leases maturity period	'5 years
Number of lease renewal options	2

License_Agreements_Additional_

License Agreements - Additional Information (Detail) (USD $)

1 Months Ended

3 Months Ended

6 Months Ended

3 Months Ended

6 Months Ended

1 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

12 Months Ended

0 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

6 Months Ended

1 Months Ended

Jan. 31, 2014

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2014

Jun. 30, 2013

Jan. 31, 2014

Oct. 05, 2011

Mar. 31, 2012

Jun. 30, 2014

Dec. 31, 2013

Oct. 05, 2011

Dec. 31, 2013

Mar. 15, 2012

Jun. 30, 2014

31-May-13

Jun. 30, 2014

31-May-13

Upfront payment [Member]

Upfront payment [Member]

Upfront payment [Member]

Upfront payment [Member]

Allegro stockholders [Member]

Grupo Ferrer Internacional, S.A. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Grupo Ferrer Internacional, S.A. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Teva Pharmaceuticals USA, Inc. [Member]

Allegro stockholders [Member]

Allegro stockholders [Member]

Private Placement [Member]

Allegro stockholders [Member]

License Agreements [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Upfront cash received under collaborative arrangement

'

'

'

'

'

'

'

'

'

'

$10,000,000

'

'

'

'

'

'

'

$40,000,000

'

'

Payments to former stockholders under collaborative arrangement

'

'

'

'

'

'

'

'

'

250,000

'

'

'

'

5,000,000

312,500

'

'

'

'

10,000,000

Eligible receipt of additional milestone payments

'

'

'

'

'

'

'

'

'

'

51,000,000

'

'

48,000,000

'

'

'

'

195,000,000

'

'

License agreement contractual terms

'

'

'

'

'

'

'

'

'

'

'

'

'Until the later of the last to expire patent covering ADASUVE in such country or 12 years after first commercial sale.

'

'

'

'

'

'

'

'

License agreement term period

'

'

'

'

'

'

'

'

'

'

'

'

'12 years

'

'

'

'

'

'

'

'

Aggregate purchase price

'

'

'

'

'

'

'

'

'

'

'

241,936

'

'

'

'

'

'

'

'

'

Purchase of common stock, value

'

'

'

'

'

'

'

'

'

'

'

3,000,000

'

'

'

'

'

'

'

'

'

Common stock price, per share

'

'

'

'

'

'

'

'

'

'

'

$12.40

'

'

'

'

'

'

'

'

'

Premium on the fair value from sale of stock, classified as deferred revenue

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

1,452,000

'

'

'

'

Estimated performance period of agreement

'

'

'

'

'

'

'

'

'

'

'

'

'4 years

'

'

'

'

'

'

'

'

Revenue under agreement

'

368,000

43,529,000

2,097,000

44,258,000

364,000

729,000

1,093,000

1,093,000

'

'

'

'

'

'

'

'

'

'

'

'

Deferred revenue

'

4,008,000

'

4,008,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Upfront cash received under collaborative arrangement

1,000,000

'

'

'

'

'

'

'

'

'

'

'

'

1,250,000

'

'

'

'

'

'

'

Sale of notes backed by royalty and milestone payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

45,000,000

'

Guarantee of notes

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The notes have no recourse to us, other than to our equity interest in our wholly-owned subsidiary, and we did not guarantee the notes.

'

Aggregate term loan advances

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

Number of years from effective date to receive note advances

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

Expected volatility rate

'

'

'

87.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

70.00%

'

'

Estimated debt yield

'

'

'

0.00%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15.00%

'

'

Fair value of right-to-borrow note

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

2,800,000

'

'

Interest expense amortization period

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'2 years

'

'

Borrowing under loan agreement

'

'

'

50,830,000

0

'

'

'

'

'

'

'

'

'

'

'

'

25,000,000

'

'

'

Eligible receipt of additional payments

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$195,000,000

'

Autoliv_Manufacturing_and_Supp1

Autoliv Manufacturing and Supply Agreement - Additional Information (Detail) (Autoliv ASP, Inc. [Member], USD $)	1 Months Ended			6 Months Ended
	Apr. 30, 2014	Feb. 28, 2011	Jun. 30, 2010	Jun. 30, 2014
	ManufacturingSites			Package
Debt Instrument [Line Items]	'	'	'	'
Production of Chemical Heat Packages	'	'	'	10,000,000
Amount of cash paid to Autoliv ASP, Inc.	'	'	$4,000,000	'
Value of cancelled note	'	4,000,000	'	'
Number of manufacturing cells built	2	'	'	'
Each additional manufacturing cell cost	2,100,000	'	'	'
Original Note [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Value of unsecured promissory note issued	'	4,000,000	4,000,000	'
New Note [Member]	'	'	'	'
Debt Instrument [Line Items]	'	'	'	'
Value of unsecured promissory note issued	'	2,800,000	'	'
Value of cancelled note	'	4,000,000	'	'
Installment period of New Note	'	'48 months	'	'
Periodic payment of New Note	'	$68,000	'	'